Recombinant Human C5a Protein
Beta LifeScience
SKU/CAT #: BLPSN-0486
Recombinant Human C5a Protein
Beta LifeScience
SKU/CAT #: BLPSN-0486
Catalog No.: BLPSN-0486
Product Overview
| Tag | N/A |
| Host Species | Human |
| Accession | NP_001726.2 |
| Synonym | C5a, C5b, C5D, C5Da, Complement 5a, CPAMD4, ECLZB |
| Background | C5a is a protein fragment released from complement component C5. This 74 amino acid peptide in humans is generated by the cleavage of C5a convertase on the C5 alpha-chain during the classical, alternative, and lectin pathways of complement activation. The structure of C5a includes a core region consisting of four, anti-parallel alpha-helices held together by three disulfide linkages and a structured C-terminal tail, and C5a is rapidly metabolised by carboxypeptidase B to a 73 amino acid low activity form, C5a des-Arg. C5a is an extremely potent proinflammatory mediator, as well as a potent chemotactic factor for neutrophils and other leukocytes. It causes histamine release, increases in vascular permeability, induces several cytokines production from leukocytes, enhances neutrophil-endothelial cell adhesion, and augments the humoral and cell-mediated immune response. C5a is quickly metabolised by carboxypeptidases, forming the less potent C5adesArg. Acting via a classical G protein-coupled receptor, CD88, C5a and C5adesArg exert a number of effects essential to the innate immune response, while their actions at the more recently discovered non-G protein-coupled receptor, C5L2 (or GPR77), remain unclear. The widespread expression of C5a receptors throughout the body allows C5a to elicit a broad range of effects. Thus, C5a has been found to be a significant pathogenic driver in a number of immuno-inflammatory diseases, making C5a inhibition an attractive therapeutic strategy. C5a is a strong chemoattractant and is involved in the recruitment of inflammatory cells such as neutrophils, eosinophils, monocytes, and T lymphocytes, in activation of phagocytic cells and release of granule-based enzymes and generation of oxidants, all of which may contribute to innate immune functions or tissue damage. Accordingly, the anaphylatoxin C5a is implicated in a variety of diseases such as rheumatoid arthritis, systemic lupus erythematosus, reperfusion injury, Alzheimer's disease, and sepsis. |
| Description | A DNA sequence encoding the active form of human C5a (Leu 679-Arg 751) was expressed. |
| Source | E.coli |
| Predicted N Terminal | Based on N-terminal sequencing analysis, the first 7 aa of C5a is: MLQKKIE |
| AA Sequence | Leu 679-Arg 751 |
| Molecular Weight | The recombinant human C5a consists of 74 a.a. and has a predicted molecular mass of 8.3 kDa which is also estimated by SDS-PAGE. |
| Purity | >94% as determined by SDS-PAGE |
| Endotoxin | Please contact us for more information. |
| Bioactivity | Measured by its ability to induce N-acetyl-beta-D-glucosaminidase release from differentiated U937 human histiocytic lymphoma cells. The ED50 for this effect is typically 5-15 ng/ml. |
| Formulation | Lyophilized from sterile PBS, pH 7.4. |
| Stability | The recombinant proteins are stable for up to 1 year from date of receipt at -70°C. |
| Usage | For Research Use Only |
| Storage | Store the protein under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |
